Archive for 1 abril 2013

Top Court in India Rejects Novartis Drug Patent – NYTimes.com

abril 1, 2013

Top Court in India Rejects Novartis Drug Patent – NYTimes.com.

“Gleevec can cost up $70,000 per year, while Indian generic versions cost about $2,500 a year.”

Clarísimo.

 

Anuncios

Indian Supreme Court Delivers Verdict in Novartis Case

abril 1, 2013

Importantísimo fallo de la Suprema Corte de India, negando a Novartis el derecho a registrar una patente reverdecida (a través del evergreening)

Indian Supreme Court Delivers Verdict in Novartis Case

Decision safeguards access to affordable medicines and prevents abusive patenting of medicines

vía Indian Supreme Court Delivers Verdict in Novartis Case | msfaccess.org.